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Context. Breast cancer survivors often experience activity-related dyspnea and exercise intolerance, but the underlying
mechanisms remain unknown.
Objectives. We evaluated physiological contributors to reduced peak oxygen uptake (VO2), with particular attention to the
role of respiratory impairment.
Methods. We compared symptom assessments, respiratory and peripheral muscle strength, pulmonary function, and
ventilatory responses to symptom-limited incremental treadmill exercise in 29 women who had survived breast cancer and 29
age-matched healthy controls.
Results. Peak VO2 was reduced more than 20%, on average, in the cancer group compared with controls (P < 0.001).
Slopes of dyspnea intensity ratings over ventilation or VO2 were >50% greater in the cancer group compared to controls
(P < 0.05). Women with breast cancer had lower lung diffusing capacity for carbon monoxide (DLCO), respiratory and limb
muscle strength, and ventilatory thresholds during exercise compared with controls (all P < 0.05). During exercise, indices of
ventilatory efficiency were similar to controls, but inspiratory capacity (IC) was lower and breathing pattern was more rapid
and shallow in the cancer group (P < 0.05). The lower peak VO2 in the cancer group was associated with greater dyspnea
intensity, and lower DLCO, IC and ventilatory threshold (all P < 0.05).
Conclusion. Breast cancer survivors had greater peripheral and respiratory muscle weakness, greater reduction of IC,
impaired lung diffusion, and evidence of deconditioning compared with controls. Exercise intolerance was multifactorial and
correlated well with the combination of these factors as well as with exertional dyspnea. Individualized physiological testing in
breast cancer survivors can identify important contributors to exercise intolerance which can be targeted for
treatment. J Pain Symptom Manage 2016;-:-e-.  2016 American Academy of Hospice and Palliative Medicine. Published by
Elsevier Inc. All rights reserved.
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Introduction dyspnea, exercise intolerance (reduced exercise ca-The number of breast cancer survivors continues to
increase as a result of population aging and advances
in modern cancer treatment.1 There is abundant evi-
dence that women successfully treated for breast can-
cer can have ongoing morbidity with symptoms ofAddress correspondence to: Denis E. O’Donnell, MD, FRCPC,
102 Stuart Street, Kingston, ON K7L 2V6, Canada. E-mail:
odonnell@queensu.ca
 2016 American Academy of Hospice and Palliative Medicine.
Published by Elsevier Inc. All rights reserved.pacity as measured by peak oxygen consumption
[VO2]), and reduced physical activity that can result
in perceived poor health status.2e6 Effective ameliora-
tion of the common symptoms of dyspnea and exer-
cise intolerance awaits a better understanding of
their underlying physiological mechanisms.Accepted for publication: February 13, 2016.
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physiological testing, including cardiopulmonary exer-
cise testing, to uncover contributory factors to unex-
plained or disproportionate dyspnea in individuals
with various cancers.6 In breast cancer patients who
are clinically stable and remote from treatment inter-
ventions, potential contributors to dyspnea and exer-
cise intolerance include the effects of the underlying
cancer, the adverse effects of chemotherapy and/or
radiotherapy, and the effects of deconditioning due
to inactivity.2e17 Indeed, the mechanisms are likely
multifactorial and may include 1) increased ventilatory
demand secondary to ventilation-perfusion abnormal-
ities7,8; 2) decreased ventilatory capacity secondary to
inspiratory muscle weakness6,9,10; 3) impaired dynamic
respiratory mechanics secondary to peripheral airway
dysfunction or lung restriction6e8,11e15; 4) impairment
of lung diffusing capacity secondary to microvascular
injury6e8,12e15; 5) cardiocirculatory impairment16,17;
or 6) any combination of the above. Several studies
have highlighted the importance of deconditioning
and reduced cardiorespiratory fitness in breast cancer
survivors, but the role of respiratory impairment per
se remains unknown.2e5,16
The present study extends the previous work by
examining specific respiratory-related contributions
to exercise intolerance in women treated for breast
cancer. Based on previous studies in various cancer
groups,6,9 we postulated that exertional dyspnea and
exercise intolerance in breast cancer survivors would
be associated, not only with increased ventilatory de-
mand secondary to deconditioning, but also with
reduced inspiratory capacity (IC) and inspiratory mus-
cle weakness. To test this hypothesis, we selected clin-
ically stable women with breast cancer who did not
have overt cardiorespiratory disease or other comor-
bidities that could contribute to exercise intolerance.
We compared physiological parameters collected at
rest and during incremental exercise in the cancer pa-
tients and age-matched healthy controls. Finally, we
examined interrelationships between exercise capac-
ity, dyspnea intensity ratings, and pertinent physiolog-
ical markers which included measures of IC,
respiratory muscle strength, and ventilatory efficiency
during exercise.Methods
This cross-sectional study analyzed a subset of data
collected in a larger sample of outpatients with cancer
and healthy controls who performed physiological
testing in our laboratory. There is no overlap between
the current analysis and that of the original study
which examined mechanisms of unexplained dyspnea
in a variety of cancer types: a portion of the largersample of data has been previously published along
with a detailed methodology.6 Of 129 subjects tested,
30 were identified as women with breast cancer, one
of whom did not meet study eligibility criteria
(see the following) because of abnormal baseline
spirometry. Thus, 29 women with breast cancer and
29 age-matched healthy women were included in this
analysis. Subjects provided written informed consent
as part of the original study. The Queen’s University
Health Sciences & Affiliated Hospitals Research
Ethics Board approved the current analysis and waived
the need for additional informed consent (DMED-
1676-14).Subjects
Adult women with breast cancer were included if
they had stable disease, a life expectancy more than
three months, and no chemotherapy or radiotherapy
in the previous three months (to allow time for recov-
ery and ensure clinical stability). Exclusion criteria
were as follows: 1) dyspnea that could be attributed
to known cardiopulmonary disease, whether cancer-
related or coexisting; 2) primary or secondary lung
cancer, chronic obstructive pulmonary disease,
asthma, ischemic heart disease, congestive heart fail-
ure, or significant cardiac arrhythmias; 3) abnormal
resting spirometry (forced expiratory volume in one
second [FEV1] <80% predicted, forced vital capacity
[FVC] <80% predicted, or FEV1/FVC<0.7); 4)
abnormal chest radiograph; 5) resting oxygen satura-
tion (SpO2) <90%; or 6) hemoglobin concentration
<100 g/L. Age-matched healthy women were re-
cruited by advertising in the community.Procedures
Height, weight, waist and hip circumferences, and
skinfold thicknesses were measured.18 Blood from
the cancer group was analyzed for complete blood
count, hemoglobin, albumin, and electrolyte concen-
trations. Chronic activity-related dyspnea was assessed
using the Baseline Dyspnea Index and modified Med-
ical Research Council dyspnea scale: Baseline Dyspnea
Index total scores range from 0 (most severe dyspnea)
to 12 (no dyspnea) and the modified Medical
Research Council dyspnea scale ranges from 0 (best)
to 4 (worst).19,20 Habitual physical activity was assessed
as either ‘‘active’’ (exercised regularly at least twice per
week) or ‘‘sedentary.’’
Spirometry, body plethysmography, diffusing capac-
ity of the lung for carbon monoxide (DLCO), and
maximal inspiratory and expiratory mouth pressures
(MIP, MEP) were measured (Vmax 229d and Autobox
6200 DL; SensorMedics, Yorba Linda, CA) according
to recommended standards.21e24 Measurements were
expressed relative to predicted normal values.25e31
Table 1
Subject Characteristics
Characteristic
Breast
Cancer
(n ¼ 29)
Healthy
Control
(n ¼ 29)
Age, yrs 61  12 59  11
Height, cm 162  6 164  4
Weight, kg 73  15 71  12
Weight, % of ideal 116  21 111  20
Body mass index, kg/m2 27.7  4.9 26.2  4.9
Waist-to-hip ratio 0.82  0.07 0.81  0.07
Skinfold thickness (sum of 5), mm 90  37 96  33
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ercise tests were performed on a treadmill (Medtrack
ST55 with Q710; Quinton Instrument Co., Bothell,
WA) using SensorMedics Vmax 229d testing equip-
ment as previously described.6 In addition to breath-
by-breath measurements, assessments included SpO2
by pulse oximetry; heart rate (HR) by electrocardiog-
raphy; blood pressure by auscultation; serial IC mea-
surements for evaluation of operating lung
volumes32; and intensity of perceived breathing and
leg discomfort rated with the modified 10-point Borg
scale.33 Data were averaged in 30-second intervals
throughout the test, and ‘‘peak exercise’’ data were
averaged over the last 30 seconds of exercise. Peak
VO2 was compared with predicted normal values ac-
counting for sex, age, height, and weight; a 9% correc-
tion factor was applied to estimate the difference
between treadmill and cycle testing.34 Ventilatory
(anaerobic) thresholds were determined by
combining three methods.35 Relationships between
tidal volume (VT) and minute ventilation (VE) were
examined, and the inflection point was determined
for each subject to represent the onset of mechanical
constraints on VT expansion.
36 Expiratory flow limita-
tion was crudely assessed by comparing the overlap
of tidal flow-volume loops with the maximal flow-
volume loop.37 Maximum ventilatory capacity was esti-
mated as 35  FEV1.38
Leg (knee) and arm (elbow) strength were
measured using a computerized isokinetic dynamom-
eter (Cybex International, Medway, MA). Peak torque
was averaged from four maximal flexion/extension ef-
forts made for each joint at a 90/s angular velocity.Cancer stage, n (%)
1 14 (48.3) d
2 5 (17.2)
3 5 (17.2)
4 5 (17.2)
Cancer treatment, n (%)
Surgery 28 (96.6) d
Radiotherapy 23 (79.3)
Chemotherapy 10 (34.5)
Hormonal therapy 18 (62.1)
Time since last cancer treatment,a
months
33  39 d
Cigarette smoking history, pack-years 6  11 2  4
Cigarette smoking status, n (%)
Current 1 (3.4) 0 (0)
Never 13 (44.8) 16 (55.2)
Exsmoker 15 (51.7) 13 (44.8)
Habitually active, n (%) 15 (51.7) 17 (58.6)
Baseline Dyspnea Index total
score (0e12)
8.0  2.8b 11.2  1.1
Modified MRC dyspnea scale (0e4) 1.1  1.0b 0.3  0.5
Muscle torque (90 /s), Nm
Elbow extension 18.2  5.8b 23.9  4.9
Elbow flexion 19.2  6.6b 24.9  4.2
Knee extension 60.5  21.8b 78.9  21.8
Knee flexion 41.0  17.6b 55.2  15.7
MRC ¼ Medical Research Council.
Values are means  SD or n.
aSurgery, radiotherapy, or chemotherapy.
bP < 0.05, breast cancer versus healthy control group.Statistical Analysis
A significance level of P < 0.05 was used for all ana-
lyses. Data are reported as means  SD unless specified
otherwise. Although an a priori sample size was not esti-
mated for this retrospective analysis, the sample size of
29 per group provides greater than 80% power to
detect a 20% difference in peak VO2, assuming an SD
similar to that in this study and others.2e5 Group com-
parisons were made using unpaired t-tests for contin-
uous variables and the Pearson’s chi-square test for
categorical variables. Comparisons were made for
linear exercise response slopes and for measurements
at rest, the VT/VE inflection point, the ventilatory
threshold and peak exercise. Pearson correlations
were conducted to evaluate simple associations be-
tween variables. To evaluate the relationship between
peak VO2 (dependent variable) and relevant indepen-
dent variables during exercise, the following were
included in a multivariable linear regression model:
the independent variable of interest, group as a cate-
gorical effect, and an interaction term to determinewhether the relationship being tested was similar across
groups (variable  group). Independent variables
included measurements of pulmonary function, respi-
ratory and limb muscle strength, the ventilatory
threshold, and symptom intensity slopes (dyspnea/VE,
dyspnea/VO2, leg discomfort/VO2). Forward stepwise
multiple regression analysis incorporating group as a
categorical effect was carried out with significant inde-
pendent variables. Analyses were conducted using Sy-
stat 6.1 (Systat Software Inc., San Jose, CA).Results
Subject characteristics and breast cancer stage are
presented in Table 1. There were no significant
between-group differences in demographics or an-
thropometrics. All subjects were aged older than
35 years and had a body mass index (BMI) between
18.5 and 35 kg/m2, except one underweight
(16.1 kg/m2) cancer patient who had always been un-
derweight and one subject per group with a BMI
Table 3
Peak Incremental Exercise
Measurement
Breast
Cancer
Healthy
Control
Reason for stopping exercise, n (%)
4 Vol. - No. - - 2016O’Donnell et al.between 35 and 40 kg/m2. Chronic activity-related dys-
pnea was greater in the cancer group than in controls.
Subjects were habitually physically active in 52% and
59% of the cancer and control group, respectively.
Smoking history was similar across groups: the major-
ity were nonsmokers or remote exsmokers with only
one current smoker in the cancer group.
Cancer treatments varied and included lumpectomy
(n ¼ 9) or mastectomy (n ¼ 19); radiotherapy
(n ¼ 23); and chemotherapy (n ¼ 10) and/or drug
therapy with either tamoxifen or anastrozole
(n ¼ 18; n ¼ 5 of these in combination with chemo-
therapy). The majority received two or more types of
treatment (surgery plus chemotherapy and/or radio-
therapy), whereas three women had only surgery
with hormone drug therapy. The cancer group had
no significant abnormalities in serum albumin or elec-
trolyte concentrations. Blood hemoglobin concentra-
tion was 136  11 g/L, hematocrit was 0.40  0.03,
and resting oxyhemoglobin saturation was
95.6  1.8% in the cancer group.
Pulmonary function measurements were, on
average, within normal ranges, but the cancer group
had a significantly lower IC, total lung capacity
(TLC), DLCO, maximal midexpiratory flow (FEF50),
and MIP compared to controls (Table 2). The lower
DLCO (corrected for hemoglobin) in the cancer
group was accompanied by a lower DLCO relative toTable 2
Resting Pulmonary Function
Measurement
Breast
Cancer
(n ¼ 29)
Healthy
Control
(n ¼ 29)
FEV1, % predicted 107  18 114  15
FEV1/FVC, % 77  6 79  4
PEF, % predicted 103  24 111  20
FEF50, % predicted 63  22a 77  20
IC, % predicted 97  17a 108  23
SVC, % predicted 105  15 110  13
FRC, % predicted 102  13 104  19
RV, % predicted 96  13 103  22
TLC, % predicted 100  9a 106  10
sRaw, % predicted 146  54 149  65
DLCO, % predicted 81  21a 98  15
DLCO adjusted for
Hb, % predicted
84  21a d
DLCO/VA, % predicted 101  20a 112  16
VA, % TLC 85  9 86  8
MIP, cm H2O
(% predicted)
51  20 (82  29)a 65  25 (102  38)
MEP, cm H2O
(% predicted)
79  33 (57  24) 93  34 (66  24)
FEV1 ¼ forced expiratory volume in one second; FVC ¼ forced vital capacity;
PEF ¼ peak expiratory flow; FEF50 ¼ forced expiratory flow at 50% of forced
vital capacity; IC ¼ inspiratory capacity; SVC ¼ slow vital capacity;
FRC ¼ functional residual capacity; RV ¼ residual volume; TLC ¼ total
lung capacity; sRaw ¼ specific airway resistance; DLCO ¼ diffusing capacity
of the lung for carbon monoxide; Hb ¼ hemoglobin; VA ¼ alveolar volume;
MIP ¼ maximal inspiratory mouth pressure; MEP ¼ maximal expiratory
mouth pressure.
Values are means  SD.
aP < 0.05 cancer versus control group.alveolar volume (DLCO/VA) (r ¼ 0.750, P < 0.0005):
although DLCO was within normal limits on average
in the cancer group, n ¼ 2 had a moderate-to-severe
reduction (<60% predicted) and n ¼ 12 had a mild
reduction (60%e80% predicted), in contrast to only
n ¼ 3 with a mildly reduced DLCO in the control
group. Limb muscle strength was significantly reduced
in the cancer group compared to controls (Table 1).
Across groups, respiratory muscle strength (MIP and
MEP) correlated significantly with leg strength (knee
flexion and extension) (all relationships P < 0.01).
Exercise Responses
Peak exercise data are presented in Table 3.
Compared with controls, cancer patients had a signif-
icantly lower peak VO2. A ventilatory threshold was
identified in all but one subject per group and
occurred at a VO2 of 14.9  2.9 and 18.1  3.5 mL/
kg/minute or 58  9 and 65  10% of predicted
maximum in the cancer and control groups, respec-
tively (P < 0.0005). Twenty-one (72%) cancer subjectsDyspnea 13 (45) 12 (41)
Leg discomfort 8 (28) 5 (17)
Both dyspnea and leg
discomfort
1 (7) 3 (10)
Fatigue 5 (17) 1 (3)
Other 1 (3)a 8 (28)
Dyspnea, Borg units 4.2  2.3 4.0  1.9
Leg discomfort, Borg units 3.6  2.2 3.3  2.3
VO2, L/minute 1.55  0.44a 2.04  0.59
VO2, % predicted maximum 83  3a 105  4
VO2, mL/kg/minute 21.4  5.0a 29.1  8.6
Heart rate, % predicted
maximum
86  10 88  7
RER 1.03  0.11 1.08  0.10
SpO2, % 93.4  3.5 92.2  3.5
PETCO2, mm Hg 43.2  5.8 44.4  4.3
VE, L/minute 45.1  14.1a 60.0  16.7
VE/VCO2 28.5  4.4 27.7  3.9
VE, % MVC 57  17 65  16
Fb, breaths/min 31.6  5.4a 35.3  6.5
TI/TTOT 0.46  0.03 0.47  0.02
VT, L 1.42  0.35a 1.70  0.39
VT/IC, % 72  14 77  12
IC, L 1.97  0.36a 2.21  0.35
DIC peak rest, L 0.17  0.26 0.23  0.30
IRV, L 0.55  0.32 0.51  0.25
EILV, % TLC 89  6 91  5
Expiratory flow limitation,
% VT overlap
12  19 11  23
VO2 ¼ oxygen uptake; RER ¼ respiratory exchange ratio; SpO2 ¼ oxygen
saturation measured by pulse oximetry; PETCO2 ¼ partial pressure of end-
tidal carbon dioxide; VE ¼ minute ventilation; MVC ¼ maximum ventilatory
capacity estimated as 35  FEV1; Fb ¼ breathing frequency; TI/
TTOT ¼ inspiratory time over total breath time (inspiratory duty cycle);
VT ¼ tidal volume; IC ¼ inspiratory capacity; IRV ¼ inspiratory reserve vol-
ume; EILV ¼ end-inspiratory lung volume; TLC ¼ total lung capacity.
Values are means  SD.
aP < 0.05, cancer versus control group.
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following criteria of a maximal response: peak
VO2 $ 85% predicted, peak HR > 90% predicted,
or respiratory exchange ratio > 1.1.39 Of those not
meeting these criteria, all had an inspiratory reserve
volume (IRV) <1L suggestive of a ventilatory
constraint. Reasons for stopping exercise were not
different between groups with regard to selection fre-
quency of dyspnea, legs, the combination of dyspnea
and legs, and fatigue; other reasons were reported
by one cancer subject (lightheadedness) and eight
controls (panic, too hot, hip/knee/calf pain, dizzi-
ness, claustrophobia, dry mouth) (Table 3).
Selected cardiopulmonary exercise responses are
shown in Figure 1. Compared with controls, cancer pa-
tients reached a lower peak VE but VE/VCO2 relation-
ships were similar: VE-VCO2 slopes and intercepts,
VE/VCO2 at the ventilatory threshold, and the VE/
VCO2 nadir were not significantly different between
groups. The cancer group reached a similar peak HR
but had a steeper HR/VO2 slope (P < 0.005)
compared with controls. There was no group differ-
ence in SpO2 during exercise.
Breathing pattern and lung volume responses are
shown in Figure 2. Peak VT was significantly lower in
the cancer group than in controls. An inflection in
the VT/VE relationship occurred at a lower VT
(1.33  0.31 vs. 1.61  0.41 L; P ¼ 0.005) and at an
earlier VE (32.2  8.4 vs. 41.5  11.2 L/minute;
P < 0.001) and VO2 (71  16 vs. 87  19% predicted
maximum; P ¼ 0.001) in cancer vs. control subjects;
thereafter, increases in VE were accomplished primarily
by increasing breathing frequency (Fb). The diminished
VT response to exercise was driven by reductions in IC
(and IRV), thus both groups reached a similar critically
reduced IRV at end exercise. The extent of dynamic hy-
perinflation during exercise (change in IC from rest)
was similar across groups. Some degree of expiratory
flow limitation was present in four and two subjects at
rest and in 10 and six subjects at peak exercise in the
cancer and control groups, respectively. Across groups,
significant interrelationships were found between MIP
% predicted, IC% predicted at rest and during exercise,
peak VT, and peak VE (all P < 0.005).
Exertional dyspnea intensity expressed as a slope
against either VE or VO2 was greater (P < 0.05) in can-
cer patients than controls (Fig. 3). Slopes of leg
discomfort ratings over VO2 were also greater
(P < 0.05) in cancer patients than controls (Fig. 3).
An exploratory subgroup analysis within the cancer
group showed no significant differences between pa-
tients who received chemotherapy (n ¼ 10) versus
those who did not (n ¼ 18) for any of the outcome
measures tested, that is, peak VO2, dyspnea slopes, pul-
monary function, and exercise responses.Correlates of Peak Exercise Capacity
Peak VO2 % predicted correlated well with slopes of
dyspnea/VE (P ¼ 0.006) and dyspnea/VO2
(P ¼ 0.011) but not with leg discomfort/VO2
(P ¼ 0.160). The best physiological correlates of
peak VO2 % predicted were leg strength
(P ¼ 0.001), VO2 % predicted at the ventilatory
threshold (P ¼ 0.002), DLCO/VA % predicted
(P ¼ 0.005), IC % predicted (P ¼ 0.019), DLCO% pre-
dicted (P ¼ 0.027); there were no significant group ef-
fects or group interactions for any of these
independent variables. The best combination of phys-
iological variables to explain peak VO2 % predicted
was leg strength, DLCO/VA % predicted, IC % pre-
dicted, and VO2 % predicted at the ventilatory
threshold (r2 ¼ 0.680). With only resting measure-
ments in the model, the best combination of variables
to explain peak VO2 % predicted was DLCO/VA %
predicted and IC % predicted (r2 ¼ 0.410). Age,
BMI, and cancer stage did not contribute significantly
to any relationship.Discussion
The main findings of this study were that women
treated for breast cancer, compared to controls, had
1) increased exertional symptoms and a lower peak
VO2; 2) modest but consistent reductions in lung
diffusion but no clear evidence of reduced ventilatory
efficiency during exercise; 3) reduced respiratory and
peripheral muscle strength and reduced ventilatory
thresholds during exercise; and 4) a smaller IC and
a shallower breathing pattern during exercise. The re-
sults support the hypothesis that dyspnea and exercise
intolerance in breast cancer survivors is associated not
only with increased ventilatory demand but also with
reduced IC, likely secondary to inspiratory muscle
weakness.
The cancer and control groups were well matched
for age and anthropometrics and reported similar
habitual activity levels based on direct questioning. Pa-
tients were clinically stable but reported moderate
chronic activity-related dyspnea. This was corrobo-
rated by greater dyspnea intensity and w20% lower
peak VO2 during exercise testing. Patients with back-
ground cardiorespiratory diseases or other comorbid-
ities that could contribute to exercise intolerance were
not included in the study. This allowed an evaluation,
in relative isolation, of the respiratory mechanisms of
exercise intolerance attributable to the cancer and its
treatment.
Spirometry and plethysmographic lung volumes
were similar in both groups except for a modestly
lower IC and TLC in the cancer group. In accordance
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Fig. 1. Selected cardiopulmonary responses to exercise are shown in women with breast cancer and in healthy controls. Data
are mean  SEM values plotted at rest, at each stage of exercise, at the inflection point of tidal volume (VT) relative to venti-
lation (VE), and at peak exercise. *P < 0.05 between-group difference in peak VO2; yP < 0.05 between-group difference in HR-
VO2 slopes. HR ¼ heart rate; SEM ¼ standard error of the mean; SpO2 ¼ oxygen saturation; VCO2 ¼ carbon dioxide output;
VE/VCO2 ¼ ventilatory equivalent for carbon dioxide; VO2 ¼ oxygen uptake.
6 Vol. - No. - - 2016O’Donnell et al.with previous studies, DLCO and DLCO/VA were
reduced in the cancer group, and in the absence of
airway obstruction or anemia.6e8,12e15 This suggests
microvascular injury as a consequence of prior radio-
therapy or, less likely, chemotherapy. However, the
average DLCO and DLCO/VA remained within pre-
dicted normal ranges. Patients had no documentationof radiation pneumonitis and no evidence of
treatment-related interstitial lung disease or fibrosis
on chest radiographs before study entry.
Mild-to-moderate inspiratory and peripheral muscle
weakness was present in the cancer group versus con-
trols: both measures of muscle strength were w20%
lower, on average, in the cancer group. The close
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Fig. 2. Breathing pattern and operating lung volume responses to exercise are shown in the cancer and healthy control
groups. The inflection point of the relationship between tidal volume (VT) and ventilation (arrows) occurred at a significantly
lower VT and ventilation (yP < 0.05) in the cancer group compared with controls. At this point, inspiratory reserve volume
(IRV) was critically reduced (shaded area) and breathing frequency (Fb) accelerated to sustain further increases in ventilation
in both groups. There was also a decreased IC at rest and throughout exercise in the cancer group compared with controls.
Data are mean  SEM values plotted at rest, at each stage of exercise, at the inflection point of tidal volume (VT) relative to
ventilation (VE), and at peak exercise. *P < 0.05 between-group difference in the y-axis variable at rest or at peak exercise.
IC ¼ inspiratory capacity; SEM ¼ standard error of the mean; TLC ¼ total lung capacity; VC ¼ vital capacity.
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strength across groups points to the likelihood of
generalized skeletal muscle weakness in the cancer
group. In this context, reduced nutritional status
could not be implicated by BMI, skinfold thickness, al-
bumin, electrolyte, or hemoglobin measurements.
Additionally, cancer cachexia and chemotherapy-
related myopathy or neuropathy were not clinically
identified in individual patients. By exclusion, general-
ized muscle weakness was likely the result of the effects
of reduced physical activity and skeletal muscle decon-
ditioning. Collectively, the presence of generalized
muscle weakness, a lower ventilatory threshold, higher
submaximal HRs, and greater exertional symptoms
are all compatible with lower cardiorespiratory fitness
and greater deconditioning.
The important role of respiratory factors in contrib-
uting to reduced exercise tolerance in the breast can-
cer group is supported by the associations between
peak VO2 and exertional dyspnea intensity, lung diffu-
sion, IC, and the ventilatory threshold. The question
arises: why was dyspnea intensity increased at a givenVO2 and VE in the cancer group? In general terms,
abnormal increases in activity-related dyspnea in the
clinical setting can be explained by increased neural
respiratory drive (secondary to metabolic and pulmo-
nary gas exchange abnormalities), impaired dynamic
respiratory mechanics and muscle function, or any
combination of these.40,41 In the cancer group, venti-
latory demand was relatively increased at high exercise
intensities, likely reflecting earlier metabolic acidosis
due to deconditioning as previously reported.3,16
Greater ventilation at a lower VO2, and the associated
increase in neural respiratory drive, is likely an impor-
tant source of earlier onset dyspnea in the cancer
group.
The potential contribution of increased ventilation-
perfusion inequalities and high physiological dead
space to the heightened ventilatory response was
considered, particularly in the setting of a relative,
albeit modest, DLCO reduction in the cancer group.
However, VE/VCO2 before the ventilatory threshold
and at its nadirdan index of ventilatory efficiency
and an indirect measure of physiological dead
01
2
3
4
5
0 10 20 30 40 50 60 70
D
ys
pn
ea
 (B
or
g 
un
its
)
Ventilation (L/min)
Cancer Control
0
1
2
3
4
5
0 20 40 60 80 100 120
Le
g 
di
sc
om
fo
rt 
(B
or
g 
un
its
)
VO2 (% predicted maximum)
0
1
2
3
4
5
0 20 40 60 80 100 120
D
ys
pn
ea
 (B
or
g 
un
its
)
VO2 (% predicted maximum)
*
*
*
10
10
10
Fig. 3. Exertional symptom intensity is shown in the cancer
and healthy control groups. Data are mean  SEM values
plotted at rest, at each stage of exercise, at the inflection
point of tidal volume (VT) relative to ventilation (VE), and
at peak exercise. *P < 0.05 between-group difference in
slopes. SEM ¼ standard error of the mean.
8 Vol. - No. - - 2016O’Donnell et al.spacedand other measures of pulmonary gas ex-
change were similar in both groups and cannot easily
be implicated in increasing neural respiratory drive
and associated dyspnea.
We found no evidence of significant impairment of
airway function or pulmonary gas trapping, and no in-
crease in estimates of expiratory flow limitation during
exercise in the cancer group. It follows that in the
absence of increased mechanical loading, inspiratory
muscle weakness provides a plausible explanation for
increased dyspnea intensity at any given ventilation
during exercise. The contention that significant dy-
namic inspiratory muscle weakness existed in the can-
cer group is bolstered by the fact that lower IC, MIP,peak VT, and peak VE were statistically interrelated. A
lower IC in the absence of lung hyperinflation reflects
a reduced ability to inspire to TLC because of muscle
weakness. In the cancer group, IC (and IRV) was lower
throughout exercise and consequently, the VT/VE in-
flection occurred at a w20% lower VO2 and VE. The
inability to fully expand VT at higher exercise inten-
sities meant that patients relied more on increasing
Fb to increase VE in pace with metabolic demand. In
the setting of inspiratory muscle weakness, respiratory
motor command output, central corollary discharge,
and contractile muscular effort must increase to main-
tain adequate force generation. These neurophysio-
logical perturbations, in turn, are linked to
perceived respiratory discomfort at a lower ventilation
than in healthy controls.40,41
Our results indicate that peripheral muscle weak-
ness also played an important role in exercise intoler-
ance in the cancer group: measures of leg strength
correlated well with peak VO2. Greater perceived leg
discomfort at any given VO2 in the cancer group
may reflect awareness of the increased motor com-
mand output required to drive the weakened locomo-
tor muscles. Thus, in accordance with current
theoretical constructs, greater perceived leg and respi-
ratory discomfort during exercise may share common
neurophysiological origins.40,41
Limitations
Our results may not be generalizable to all patients
with breast cancer. However, to minimize confounding
by clinical heterogeneity, our selection criteria speci-
fied presence of clinical stability, absence of radiolog-
ical and spirometric abnormalities, evidence of
adverse treatment effects, or significant comorbidities
which may be implicated in dyspnea causation and ex-
ercise intolerance. Because of the relatively small sam-
ple size and heterogeneity of cancer stage and
treatment, we could not adequately perform subgroup
analyses or determine the precise origins of the phys-
iological abnormalities we uncovered. We used patient
recall to evaluate habitual activity levels rather than
objective quantification. Because our focus was on
physiological factors in exercise intolerance, we were
unable to explore the biological basis of skeletal mus-
cle weakness. Finally, the precise etiology of the
reduced DLCO could not be determined: computed
tomography of the lungs may have revealed structural
changes of interstitial disease or fibrosis not visualized
with plain radiography.Conclusions
Women treated for breast cancer reported greater
chronic activity-related dyspnea and had objectively
Vol. - No. - - 2016 9Exercise Impairment in Breast Cancer Survivorsdiminished exercise capacity compared with healthy
controls. Women with cancer showed evidence of de-
conditioning with lower ventilatory thresholds during
standardized exercise testing, which likely contributed
to earlier onset of dyspnea. They also had general skel-
etal muscle weakness compared with controls. In the
cancer group, reduced IC and static inspiratory mus-
cle strength, a more rapid and shallow breathing
pattern, and higher dyspnea intensity ratings during
exercise were consistent with the presence of signifi-
cant dynamic inspiratory muscle weakness. The clin-
ical implication of this study is that potentially
reversible factors such as inspiratory muscle weakness
can be identified by simple tests in individual patients
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